Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.34 |
| ▸ | NPSR1 | Q6W5P4 | 2/20 | 0.34 |
| ▸ | POLB | P06746 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.32 |
| ▸ | CRHR1 | P34998 | 2/20 | 0.32 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4866079 | 0.83 | ALDH1A1 (0.32) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL17267904 | 0.79 | ALDH1A1 (0.33) | ALDH1A1NPSR1MAPTHTTSMN1; SMN2 | |
| SCHEMBL2590249 | 0.75 | SLC6A3 (0.44) | ALDH1A1NPSR1MAPTHTTKDM4E | |
| SCHEMBL15194885 | 0.74 | — | — | |
| SCHEMBL31226864 | 0.74 | MEN1 (0.32) | ALDH1A1NPSR1MAPTCRHR1 | |
| SCHEMBL4219437 | 0.73 | ALDH1A1 (0.35) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL16834246 | 0.72 | ALDH1A1 (0.37) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL5790127 | 0.72 | ALDH1A1 (0.37) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL2796756 | 0.72 | ALDH1A1 (0.34) | ALDH1A1NPSR1POLBMAPTHTT | |
| SCHEMBL29713642 | 0.72 | ALDH1A1 (0.34) | ALDH1A1NPSR1POLBMAPTHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-116171154-A | Modulators of cystic fibrosis transmembrane conductance regulator | 弗特克斯药品有限公司 | 2023-05-26 | — | — | CN | disclosed |
| US-9796662-B2 | Esteramines and derivatives from natural oil metathesis | STEPAN COMPANY (US) | 2017-10-24 | — | — | US | disclosed |
| EP-2804936-B1 | RENEWABLE FATTY ACID WAXES AND METHODS OF MAKING | ELEVANCE RENEWABLE SCIENCES (US) | 2016-03-23 | — | — | EP | disclosed |
| US-9290719-B2 | Renewable fatty acid waxes and methods of making | ELEVANCE RENEWABLE SCIENCES, INC. (US) | 2016-03-22 | — | — | US | disclosed |
| US-20160023989-A1 | ESTERAMINES AND DERIVATIVES FROM NATURAL OIL METATHESIS | STEPAN CO (US) | 2016-01-28 | — | — | US | disclosed |
| US-20130178640-A1 | RENEWABLE FATTY ACID WAXES AND METHODS OF MAKING | ELEVANCE RENWABLE SCIENCES, INC. (US) | 2013-07-11 | — | — | US | disclosed |
| WO-2011039737-A1 | IMPROVED BALLISTIC RESISTANT COMPOSITE ARTICLES WITH POLYDICYCLOPENTADIENE (PDCPD) | PALTECHNICA (IL) | 2011-04-07 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20160023989-A1 | ESTERAMINES AND DERIVATIVES FROM NATURAL OIL METATHESIS | SOAT2, SOAT1, SGMS1 | ALDH1A1 858/4885NPSR1 2791/4885POLB 824/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.